Warning letter
Nicholas Pharmacy Inc.: warning letter of Jun 9, 2003
FDA warning letter UCM147523 · Baltimore District Office
Key facts
| Reference number | UCM147523 |
|---|---|
| Company | Nicholas Pharmacy Inc. |
| Subject | Medical Oxygen/CGMP for Finished Pharmaceuticals/Adulterated/Misbranded |
| Issue date | Jun 9, 2003 |
| Posted date | Jun 9, 2003 |
| Issuing office | Baltimore District Office |
| Product type | Drugs |
| CFR sections cited | 211.194, 2, 211.22, 211.100, 211.122, 211.130, 211.150, 211.160, 211.165, 211.186, 211.192, 211.198 and 3 more |
| Country | 3 |
| Inspection city | Summersville |
| Inspection ZIP | 26651-1343 |
| Inspection start date | Mar 20, 2003 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: